Table 1.
Patient characteristics
| Patients without | Patients with | |||
|---|---|---|---|---|
| post-transplant adverse events | ||||
| n = 13 | n = 48 | |||
| No. [%] | No. [%] | |||
| Sex | ||||
| Male | 7 | (53.8) | 29 | (60.4) |
| Female | 6 | (46.2) | 19 | (39.6) |
| Age group | ||||
| <6 y | 6 | (46.2) | 15 | (31.3) |
| 6–12 y | 3 | (23.1) | 18 | (37.5) |
| 13–26 y | 4 | (30.8) | 15 | (31.3) |
| Donor | ||||
| MUD | 3 | (23.1) | 13 | (27.1) |
| MMFD | 7 | (53.8) | 31 | (64.6) |
| MFD | 1 | (7.7) | 4 | (8.3) |
| Autologous | 2 | (15.4) | 0 | (0.0) |
| Primary diagnosis | ||||
| ALL | 1 | (7.7) | 11 | (22.9) |
| ALL relapse | 0 | (0.0) | 11 | (22.9) |
| AML | 0 | (0.0) | 3 | (6.3) |
| AML relapse | 1 | (7.7) | 4 | (8.3) |
| CML | 1 | (7.7) | 2 | (4.2) |
| JMML | 1 | (7.7) | 1 | (2.1) |
| MDS | 0 | (0.0) | 4 | (8.3) |
| T-NHL | 0 | (0.0) | 1 | (2.1) |
| Solid tumors | 3 | (23.1) | 3 | (6.3) |
| Aplastic anemia | 0 | (0.0) | 1 | (2.1) |
| Neurometabolic disease | 1 | (7.7) | 3 | (6.3) |
| Immunologic disease | 2 | (15.4) | 3 | (6.3) |
| Autoimmune disease | 2 | (15.4) | 0 | (0.0) |
| Chédiak-Higashi syndrome | 1 | (7.7) | 0 | (0.0) |
| Kostmann disease | 0 | (0.0) | 1 | (2.1) |
| Neurologic disease | 0 | (0.0) | 0 | (0.0) |
| Radiation | ||||
| TLI | 0 | (0.0) | 3 | (6.3) |
| TBI | 1 | (7.7) | 7 | (14.6) |
| GvHD prophylaxis | ||||
| CsA + MTX | 3 | (23.1) | 11 | (22.9) |
| CsA | 1 | (7.7) | 6 | (12.5) |
| Acute GvHD | ||||
| Grade I | 0 | (0.0) | 11 | (22.9) |
| Grade II | 0 | (0.0) | 9 | (18.8) |
| Grade III | 0 | (0.0) | 3 | (6.3) |
| Grade IV | 0 | (0.0) | 1 | (2.1) |
Abbreviations: ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myeloid leukemia, CsA cyclosporine A, GvHD graft-versus-host disease, JMML juvenile myelomonocytic leukemia, MDS myelodysplastic syndromes, MFD matched family donor, MMFD mismatched family donor, MTX methotrexate, MUD matched unrelated donor, TBI total body irradiation, TLI total lymphoid irradiation, T-NHL T cell non-Hodgkin’s lymphoma, y year(s)